1. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
<br/><br/>2. Ascierto P A, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma[J]. Journal of Clinical Oncology, 2013, 31(26): 3205-3211.
<br/><br/>3. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study[J]. Journal of Clinical Oncology, 2012, 30(22): 2718-2724.
<br/><br/>4. Bang Y J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. The Lancet, 2010, 376(9742): 687-697.
<br/><br/>5. Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non–small-cell lung cancer: AVAPERL (MO22089)[J]. Journal of Clinical Oncology, 2013, 31(24): 3004-3011.
<br/><br/>6. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial[J]. The Lancet, 2012, 379(9816): 633-640.
<br/><br/>7. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer[J]. New England Journal of Medicine, 2012, 366(6): 520-529.
<br/><br/>8. Baselga J, Cortés J, Kim S B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. New England Journal of Medicine, 2012, 366(2): 109-119.
<br/><br/>9. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor–positive breast cancer[J]. Journal of Clinical Oncology, 2009, 27(16): 2630-2637.
<br/><br/>10. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial[J]. The lancet oncology, 2013, 14(1): 29-37.
<br/><br/>11. Berns K, Horlings H M, Hennessy B T, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer[J]. Cancer cell, 2007, 12(4): 395-402.
<br/><br/>12. Blanke C D, Demetri G D, Von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT[J]. Journal of Clinical Oncology, 2008, 26(4): 620-625.
<br/><br/>13. Camidge D R, Bang Y J, Kwak E L, et al. Activity and safety of crizotinib in patients with ALK-positive non- small-cell lung cancer: updated results from a phase 1 study[J]. The lancet oncology, 2012, 13(10): 1011-1019.
<br/><br/>14. Chapman P B, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation[J]. New England Journal of Medicine, 2011, 364(26): 2507-2516.
<br/><br/>15. Cizkova M, Dujaric M E, Lehmann-Che J, et al. Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab[J]. British journal of cancer, 2013, 108(9): 1807-1809.
<br/><br/>16. Contreras A, Herrera S, Wang T, et al. Abstract PD1-2: PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients[J]. Cancer Research, 2013, 73(24 Supplement): PD1-2-PD1-2.
<br/><br/>17. Corless C L, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib[J]. Journal of clinical oncology, 2005, 23(23): 5357-5364.
<br/><br/>18. Cui C, Mao L, Chi Z, et al. A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma[J]. Molecular Therapy, 2013, 21(7): 1456-1463.
<br/><br/>19. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis[J]. The lancet oncology, 2010, 11(8): 753-762.
<br/><br/>20. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group[J]. European Journal of Cancer, 2004, 40(5): 689- 695.
<br/><br/>21. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group[J]. European Journal of Cancer, 2004, 40(5): 689- 695.
<br/><br/>22. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours[J]. European journal of cancer, 2006, 42(8): 1093-1103.
<br/><br/>23. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy[J]. British journal of cancer, 2007, 96(8): 1166-1169.
<br/><br/>24. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer[J]. Journal of Clinical Oncology, 2008, 26(35): 5705-5712.
<br/><br/>25. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factorreceptor and in KRAS are predictive and prognostic indicators in patients with non-smallcell lung cancer treated with chemotherapy alone and in combination with erlotinib. J ClinOncol 2005;23:5900-5909.
<br/><br/>26. Esteva F J, Guo H, Zhang S, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer[J]. The American journal of pathology, 2010, 177(4): 1647-1656.
<br/><br/>27. Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small cell lung cancer[J]. Cancer discovery, 2014, 4(6): 662-673.
<br/><br/>28. Fujita T, Doihara H, Kawasaki K, et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer[J]. British journal of cancer, 2006, 94(2): 247-252.
<br/><br/>29. Gajiwala K S, Wu J C, Christensen J, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients[J]. Proceedings of the National Academy of Sciences, 2009, 106(5): 1542-1547.
<br/><br/>30. Gautschi O, Pauli C, Strobel K, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib[J]. Journal of Thoracic Oncology, 2012, 7(10): e23-e24.
<br/><br/>31. Geyer C E, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer[J]. New England Journal of Medicine, 2006, 355(26): 2733-2743.
<br/><br/>32. Gianni L, Pienkowski T, Im Y H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial[J]. The lancet oncology, 2012, 13(1): 25-32.
<br/><br/>33. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification[J]. Journal of Clinical Oncology, 2011, 29(21): 2904-2909.
<br/><br/>34. Hauschild A, Grob J J, Demidov L V, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial[J]. The Lancet, 2012, 380(9839): 358-365.
<br/><br/>35. Hodi F S, Corless C L, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin[J]. Journal of Clinical Oncology, 2013, 31(26): 3182-3190.
<br/><br/>36. Hyman D M, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations[J]. New England Journal of Medicine, 2015, 373(8): 726-736.
<br/><br/>37. Jhawer M, Goel S, Wilson A J, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab[J]. Cancer research, 2008, 68(6): 1953- 1961.
<br/><br/>38. Johnson D B, Flaherty K T, Weber J S, et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor[J]. Journal of Clinical Oncology, 2014, 32(33): 3697-3704.
<br/><br/>39. Kim K B, Kefford R, Pavlick A C, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor[J]. Journal of Clinical Oncology, 2013, 31(4): 482-489.
<br/><br/>40. Kindler H L, Friberg G, Singh D A, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer[J]. Journal of Clinical Oncology, 2005, 23(31): 8033-8040.
<br/><br/>41. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours[J]. Histopathology, 2008, 53(3): 245-266.
<br/><br/>42. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer[J]. Journal of Clinical Oncology, 2009, 27(35): 5924-5930.
<br/><br/>43. Lièvre A, Bachet J B, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab[J]. Journal of Clinical Oncology, 2008, 26(3): 374-379.
<br/><br/>44. Lievre A, Bachet J B, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer[J]. Cancer research, 2006, 66(8): 3992-3995.
<br/><br/>45. Lin N U, Diéras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer[J]. Clinical Cancer Research, 2009, 15(4): 1452-1459.
<br/><br/>46. Linardou H, Dahabreh I J, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer[J]. The lancet oncology, 2008, 9(10): 962-972.
<br/><br/>47. Long G V, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial[J]. The Lancet, 2015, 386(9992): 444-451.
<br/><br/>48. Long G V, Trefzer U, Davies M A, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial[J]. The lancet oncology, 2012, 13(11): 1087-1095.
<br/><br/>49. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR[J]. New England Journal of Medicine, 2010, 362(25): 2380-2388.
<br/><br/>50. Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial[J]. The lancet oncology, 2010, 11(9): 845-852.
<br/><br/>51. Mazières J, Zalcman G, Crinò L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort[J]. Journal of Clinical Oncology, 2015, 33(9): 992-999.
<br/><br/>52. McArthur G A, Chapman P B, Robert C, et al. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study[J]. The lancet oncology, 2014, 15(3): 323-332.
<br/><br/>53. Miles D W, Chan A, Dirix L Y, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2–negative metastatic breast cancer[J]. Journal of Clinical Oncology, 2010, 28(20): 3239-3247.
<br/><br/>54. Nagata Y, Lan K H, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients[J]. Cancer cell, 2004, 6(2): 117-127.
<br/><br/>55. Nishida T, Takahashi T, Nishitani A, et al. Sunitinib-resistant gastrointestinal stromal tumors harbor cis- mutations in the activation loop of the KIT gene[J]. International journal of clinical oncology, 2009, 14(2): 143- 149.
<br/><br/>56. Ohtsu A, Shah M A, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study[J]. Journal of Clinical Oncology, 2011: JCO. 2011.36. 2236.
<br/><br/>57. Ou S H I, Bang Y J, Camidge D R, et al. Efficacy and safety of crizotinib in patients with advanced ROS1- rearranged non-small cell lung cancer (NSCLC)[C]//ASCO Annual Meeting Proceedings. 2013, 31(15_suppl): 8032.
<br/><br/>58. Ou S H I, Kwak E L, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification[J]. Journal of thoracic oncology, 2011, 6(5): 942-946.
<br/><br/>59. Paez J G, Janne P A, Lee J C, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy[J]. Science, 2004, 304(5676): 1497-1500.
<br/><br/>60. Paik PK, Varghese AM, Sima CS, et al. Response to erlotinib in patients with EGFR mutant advanced non- small cell lung cancers with a squamous or squamous-like component. Mol Cancer Ther 2012;11:2535-2540.
<br/><br/>61. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
<br/><br/>62. Pao W, Wang T Y, Riely G J, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib[J]. PLoS Med, 2005, 2(1): e17.
<br/><br/>63. Peeters M, Douillard J Y, Van Cutsem E, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab[J]. Journal of Clinical Oncology, 2013, 31(6): 759-765.
<br/><br/>64. Peeters M, Oliner K S, Price T J, et al. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer[J]. Clinical Cancer Research, 2015, 21(24): 5469-5479.
<br/><br/>65. Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis[J]. European Journal of Cancer, 2015, 51(5): 587-594.
<br/><br/>66. Planchard D, Groen HJM, Min Kim T, et al. Interim results of a phase II study of the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib in patients with BRAF V600E mutated metastatic non-small cell lung cancer. J Clin Oncol 2015;33: Abstract 8006.
<br/><br/>67. Planchard D, Mazieres J, Riely GJ, et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients [abstract]. J Clin Oncol 2013;31(Suppl 15): Abstract 8009.
<br/><br/>68. Razis E, Bobos M, Kotoula V, et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer[J]. Breast cancer research and treatment, 2011, 128(2): 447-456.
<br/><br/>69. Robert N J, Diéras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancer[J]. Journal of Clinical Oncology, 2011, 29(10): 1252-1260.
<br/><br/>70. Robinson S D, O'Shaughnessy J A, Cowey C L, et al. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib[J]. Lung Cancer, 2014, 85(2): 326-330.
<br/><br/>71. Romond E H, Perez E A, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer[J]. New England Journal of Medicine, 2005, 353(16): 1673-1684.
<br/><br/>72. Sandler A, Gray R, Perry M C, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer[J]. New England Journal of Medicine, 2006, 355(24): 2542-2550.
<br/><br/>73. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies[J]. Cancer research, 2009, 69(5): 1851-1857.
<br/><br/>74. Schneider B P, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100[J]. Journal of Clinical Oncology, 2008, 26(28): 4672-4678.
<br/><br/>75. Sequist L V, Martins R G, Spigel D, et al. First-line gefitinib in patients with advanced non–small-cell lung cancer harboring somatic EGFR mutations[J]. Journal of Clinical Oncology, 2008, 26(15): 2442-2449.
<br/><br/>76. Sequist L V, Yang J C H, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations[J]. Journal of Clinical Oncology, 2013, 31(27): 3327-3334.
<br/><br/>77. Seymour M T, Brown S R, Middleton G, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial[J]. The lancet oncology, 2013, 14(8): 749-759.
<br/><br/>78. Shah M A, Ramanathan R K, Ilson D H, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma[J]. Journal of Clinical Oncology, 2006, 24(33): 5201-5206.
<br/><br/>79. Shaw A T, Kim D W, Mehra R, et al. Ceritinib in ALK-rearranged non–small-cell lung cancer[J]. New England Journal of Medicine, 2014, 370(13): 1189-1197.
<br/><br/>80. Shaw A T, Kim D W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J]. New England Journal of Medicine, 2013, 368(25): 2385-2394.
<br/><br/>81. Shaw A T, Ou S H I, Bang Y J, et al. Crizotinib in ROS1-rearranged non–small-cell lung cancer[J]. New England Journal of Medicine, 2014, 371(21): 1963-1971.
<br/><br/>82. Shaw A T, Yeap B Y, Solomon B J, et al. Effect of crizotinib on overall survival in patients with advanced non- small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis[J]. The lancet oncology, 2011, 12(11): 1004-1012.
<br/><br/>83. Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial[J]. The lancet oncology, 2013, 14(10): 953-961.
<br/><br/>84. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. New England Journal of Medicine, 2011, 365(14): 1273-1283.
<br/><br/>85. Sosman J A, Kim K B, Schuchter L, et al. Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib[J]. New England Journal of Medicine, 2012, 366(8): 707-714.
<br/><br/>86. Swain S M, Kim S B, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo- controlled, phase 3 study[J]. The lancet oncology, 2013, 14(6): 461-471.
<br/><br/>87. Tebbutt N C, Wilson K, Gebski V J, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study[J]. Journal of Clinical Oncology, 2010, 28(19): 3191-3198.
<br/><br/>88. Van Cutsem E, de Haas S, Kang Y K, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial[J]. Journal of Clinical Oncology, 2012: JCO. 2011.39. 9824.
<br/><br/>89. Van Cutsem E, Vervenne W L, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer[J]. Journal of Clinical Oncology, 2009, 27(13): 2231-2237.
<br/><br/>90. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. New England Journal of Medicine, 2012, 367(19): 1783-1791.
<br/><br/>91. Wu Y L, Zhou C, Hu C P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial[J]. The lancet oncology, 2014, 15(2): 213-222.
<br/><br/>92. Xiao L, Yang S C, Hao J, et al. Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis[J]. Cancer letters, 2015, 359(1): 148-154.
<br/><br/>93. Yang J C H, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations[J]. Journal of Clinical Oncology, 2013: JCO. 2012.46. 1764.
<br/><br/>94. Zhu C Q, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21[J]. Journal of Clinical Oncology, 2008, 26(26): 4268-4275.